What is the management of Diabetic Ketoacidosis (DKA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Diabetic Ketoacidosis (DKA)

The standard treatment of DKA requires aggressive intravenous hydration, continuous intravenous insulin, correction of electrolytes, and treatment of the underlying cause. 1

Diagnosis and Classification

DKA is diagnosed based on the following criteria:

  • Blood glucose >250 mg/dL
  • Arterial pH <7.3
  • Serum bicarbonate <18 mEq/L
  • Presence of ketones in blood or urine
  • Anion gap >10-12 mEq/L 1, 2

DKA severity classification:

  • Mild: pH 7.25-7.30, bicarbonate 15-18 mEq/L
  • Moderate: pH 7.00-7.24, bicarbonate 10-15 mEq/L
  • Severe: pH <7.00, bicarbonate <10 mEq/L 2

Initial Assessment and Monitoring

Initial laboratory evaluation should include:

  • Plasma glucose
  • Blood urea nitrogen/creatinine
  • Serum ketones
  • Electrolytes (with calculated anion gap)
  • Osmolality
  • Arterial blood gases
  • Complete blood count with differential
  • Urinalysis and urine ketones
  • ECG 2

Obtain bacterial cultures (urine, blood, throat) if infection is suspected and initiate appropriate antibiotics.

Treatment Protocol

1. Fluid Therapy

  • Initial fluid: 0.9% NaCl at 15-20 mL/kg/h (1-1.5 L in average adult) during first hour 2, 1
  • Continue with 500-1000 mL/h until dehydration is corrected 1
  • Subsequent fluid choice depends on hydration state, electrolytes, and urine output

2. Insulin Therapy

  • Start with IV bolus of regular insulin 0.15 U/kg
  • Follow with continuous infusion at 0.1 U/kg/h (typically 5-7 U/h in adults)
  • Adjust based on blood glucose levels 1
  • For mild DKA, subcutaneous rapid-acting insulin may be considered (initial dose 0.4-0.6 U/kg followed by 0.1 U/kg) 1

3. Electrolyte Replacement

  • Potassium: Start replacement when serum K+ <5.5 mEq/L and adequate urine output is present
    • Add 20-30 mEq potassium (2/3 KCl and 1/3 KPO₄) per liter of solution 1
  • Phosphate: Consider replacement in patients with cardiac dysfunction, anemia, respiratory depression, or serum phosphate <1.0 mg/dL 1
  • Bicarbonate: Generally not recommended unless pH <6.9 1, 2

4. Monitoring

  • Blood glucose: Every 1-2 hours
  • Electrolytes, BUN, creatinine: Every 2-4 hours
  • Venous pH and bicarbonate: Every 4-6 hours
  • Strict fluid balance monitoring 1

Transition from IV to Subcutaneous Insulin

  1. Administer basal insulin (0.2 units/kg) 2-4 hours before stopping IV insulin to prevent rebound hyperglycemia 1, 2
  2. Continue IV insulin until metabolic acidosis resolves 2
  3. Initiate NPH insulin at 0.6-1 U/kg/day approximately 12 hours after treatment initiation 3

Discharge Criteria and Planning

Discharge criteria:

  • Blood glucose <200 mg/dL
  • Serum bicarbonate ≥18 mEq/L
  • Venous pH ≥7.3
  • Normalized anion gap 1

Discharge planning should include:

  • Education on recognition, prevention, and management of DKA 2
  • Medication changes
  • Follow-up needs
  • Transmission of discharge summaries to primary care providers
  • Scheduling follow-up appointments 1

Special Considerations

Euglycemic DKA

  • Defined as blood glucose <200 mg/dL with other DKA criteria present
  • Associated with SGLT2 inhibitor use, pregnancy, reduced food intake, insulin reduction/omission 1
  • Requires same management approach as traditional DKA

SGLT2 Inhibitors

  • Discontinue 3-4 days before scheduled surgeries 2, 1
  • Can precipitate euglycemic DKA 1

Perioperative Management

  • Monitor blood glucose every 2-4 hours while NPO
  • Administer short or rapid-acting insulin as needed
  • Target perioperative glucose: 80-180 mg/dL 2

Prevention of Recurrent DKA

  • Patient education on sick-day management
  • Ensure access to insulin and supplies
  • Regular follow-up with healthcare providers
  • Identification and management of precipitating factors 1

Complications to Watch For

  • Cerebral edema (particularly in pediatric patients)
  • Hypoglycemia from excessive insulin
  • Hypokalemia from insulin therapy and inadequate replacement
  • Hyperchloremic metabolic acidosis from excessive normal saline
  • Acute respiratory distress syndrome
  • Thromboembolism 4

By following this structured approach to DKA management, clinicians can effectively treat this serious condition while minimizing complications and reducing mortality.

References

Guideline

Diabetic Ketoacidosis Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.